Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
HK Stock MarketDetailed Quotes
LIVZON PHARMA (01513)
- 27.740
- -0.080-0.29%
Trading May 7 14:25 CST
24.63BMarket Cap11.08P/E (TTM)
28.180High27.640Low195.76KVolume28.180Open27.820Prev Close5.43MTurnover0.07%Turnover Ratio10.99P/E (Static)887.91MShares41.85052wk High1.50P/B8.32BFloat Cap24.90152wk Low1.22Dividend TTM299.81MShs Float41.850Historical High1.221Dividend LFY1.94%Range %0.347Historical Low27.749Avg Price100Lot Size4.40%Div Yield TTM4.40%Div Yield LFY
LIVZON PHARMA (01513) Cash Flow
All
YOY
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | 4.62%2.41B | ---- | 14.51%1.55B | ---- | 21.44%2.3B | ---- | 15.38%1.35B | ---- | -2.96%1.9B |
| Profit adjustment | ||||||||||
| Investment loss (gain) | ---- | -187.97%-50.07M | ---- | -81.59%-28.28M | ---- | 71.87%-17.39M | ---- | 68.30%-15.57M | ---- | -40.14%-61.82M |
| Impairment and provisions: | ---- | -42.13%109.23M | ---- | -46.62%17.27M | ---- | -41.58%188.76M | ---- | -38.68%32.35M | ---- | 164.17%323.1M |
| -Other impairments and provisions | ---- | -42.13%109.23M | ---- | -46.62%17.27M | ---- | -41.58%188.76M | ---- | -38.68%32.35M | ---- | 164.17%323.1M |
| Revaluation surplus: | ---- | -216.45%-17.98M | ---- | -56.76%7.95M | ---- | -39.81%15.44M | ---- | -43.33%18.39M | ---- | -65.92%25.65M |
| -Other fair value changes | ---- | -216.45%-17.98M | ---- | -56.76%7.95M | ---- | -39.81%15.44M | ---- | -43.33%18.39M | ---- | -65.92%25.65M |
| Asset sale loss (gain): | ---- | 101.19%537.86K | ---- | 95.87%149.72K | ---- | -26,621.05%-45.2M | ---- | -76.71%76.44K | ---- | 119.80%170.44K |
| -Loss (gain) on sale of property, machinery and equipment | ---- | 101.19%537.86K | ---- | 95.87%149.72K | ---- | -26,621.05%-45.2M | ---- | -76.71%76.44K | ---- | 119.80%170.44K |
| Depreciation and amortization: | ---- | -0.12%626.48M | ---- | -7.78%313.37M | ---- | -29.36%627.24M | ---- | -33.79%339.81M | ---- | 29.50%887.9M |
| -Amortization of intangible assets | ---- | -1.47%39.26M | ---- | -5.46%18.86M | ---- | -86.49%39.85M | ---- | -90.55%19.95M | ---- | 95.96%294.99M |
| -Other depreciation and amortization | ---- | 0.67%52.45M | ---- | -57.30%27.85M | ---- | 9.52%52.1M | ---- | 76.92%65.22M | ---- | 42.84%47.58M |
| Financial expense | ---- | -15.28%73.71M | ---- | -40.98%28.59M | ---- | -8.37%87M | ---- | 7.56%48.45M | ---- | 141.07%94.96M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | 3,092.83%398.57M | ---- | 368.63%271.49M | ---- | 96.02%-13.32M | ---- | 123.85%57.93M | ---- | 32.92%-334.42M |
| Accounts receivable (increase)decrease | ---- | -203.28%-279.1M | ---- | 39.38%-187.02M | ---- | -42.04%270.24M | ---- | 2.96%-308.49M | ---- | 170.60%466.29M |
| Accounts payable increase (decrease) | ---- | 84.82%-58.99M | ---- | -2,603.67%-262.61M | ---- | -235.76%-388.51M | ---- | 197.25%10.49M | ---- | -111.18%-115.71M |
| Special items of business | 12.80%817.49M | -37.01%-68.39M | 9.42%2.53B | -211.03%-25.21M | -21.59%724.73M | -176.53%-49.92M | 4.32%2.31B | -126.89%-8.1M | 208.30%924.25M | 2.65%65.22M |
| Net cash from operations | 12.80%817.49M | 5.58%3.15B | 9.42%2.53B | 10.26%1.69B | -21.59%724.73M | -8.31%2.98B | 4.32%2.31B | 24.67%1.53B | 208.30%924.25M | 17.18%3.25B |
| Cash flow from investment activities | ||||||||||
| Dividend received - investment | -11.08%8.94M | 108.91%33.94M | 117.01%27.86M | 82.20%12.75M | 72.24%10.05M | -88.82%16.25M | -81.69%12.84M | -73.77%7M | -77.77%5.83M | 11.16%145.27M |
| Sale of fixed assets | 78.84%393.87K | 25.75%1.99M | 204.59%1.28M | 426.52%1.23M | 9.38%220.23K | -89.06%1.58M | -94.30%420.61K | 339.89%233.14K | --201.34K | 388.87%14.46M |
| Purchase of fixed assets | 35.33%-90.15M | -0.70%-574.14M | -22.25%-495.41M | -43.14%-386.75M | 10.43%-139.4M | 30.51%-570.16M | 26.94%-405.24M | 32.30%-270.18M | -6.29%-155.62M | 12.73%-820.45M |
| Acquisition of subsidiaries | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---22.46M |
| Recovery of cash from investments | 14,174.98%2.22B | 994.99%7.57B | 1,020.15%4.91B | 591.95%2.8B | --15.57M | 46.56%691.12M | 17.00%437.98M | 7.94%404.07M | ---- | --471.56M |
| Cash on investment | -2,606.97%-3B | -1,024.15%-8.93B | -802.15%-6.06B | -722.68%-2.99B | 64.02%-110.64M | -67.85%-794.18M | -64.83%-671.91M | 10.87%-363.36M | -4,873.46%-307.55M | -18.53%-473.16M |
| Other items in the investment business | -191.49%-2.25M | -37,556.11%-1.86B | -212.69%-4.39M | -377.10%-4.44M | 1,313.51%2.46M | 79.04%-4.95M | 93.32%-1.4M | 89.60%-931.04K | -105.11%-202.36K | 2.42%-23.6M |
| Net cash from investment operations | -285.97%-855.88M | -469.57%-3.76B | -159.25%-1.63B | -155.65%-570.54M | 51.51%-221.75M | 6.78%-660.33M | -13.25%-627.32M | 48.94%-223.17M | -605.48%-457.34M | 42.40%-708.37M |
| Net cash before financing | -107.63%-38.39M | -126.57%-616.02M | -46.50%899.1M | -14.57%1.12B | 7.72%502.98M | -8.74%2.32B | 1.33%1.68B | 65.38%1.31B | 98.72%466.91M | 64.67%2.54B |
| Cash flow from financing activities | ||||||||||
| New borrowing | 166.13%1.68B | -33.34%3.91B | -4.46%2.87B | -9.79%1.79B | -1.96%630.14M | 60.37%5.87B | 9.99%3B | 6.88%1.98B | -37.81%642.75M | -1.51%3.66B |
| Refund | -133.08%-1.77B | 19.71%-4.84B | 3.57%-2.94B | -3.26%-2.16B | 37.68%-760.24M | -92.84%-6.03B | -30.65%-3.04B | -72.20%-2.09B | -104.81%-1.22B | -11.44%-3.13B |
| Dividends paid - financing | -2,577.55%-336.89M | 31.80%-1.14B | 31.30%-1.13B | -10.32%-785.43M | 47.17%-12.58M | 11.89%-1.67B | 11.04%-1.64B | 24.09%-711.94M | 23.58%-23.82M | -19.14%-1.9B |
| Absorb investment income | --15M | -87.92%28.8M | -82.20%28.8M | ---- | ---- | 211.51%238.4M | 312.21%161.75M | 324.93%156.33M | 115.00%79.1M | 81.15%76.53M |
| Other items of the financing business | 97.88%-7.32M | 30.06%-623.89M | -49.24%-586.79M | -182.60%-415.21M | -159.90%-345.23M | -141.28%-892.06M | -7.89%-393.18M | 4.03%-146.93M | -4.69%-132.83M | -360.70%-369.72M |
| Net cash from financing operations | 13.06%-424.2M | -7.14%-2.66B | 8.45%-1.75B | -94.36%-1.57B | 25.47%-487.92M | -50.03%-2.49B | -8.14%-1.91B | -96.57%-805.74M | -306.71%-654.61M | -130.01%-1.66B |
| Effect of rate | -423.13%-59.84M | -1,213.21%-98.11M | -165.19%-56.63M | -1,007.14%-26.04M | -1,557.26%-11.44M | -56.03%8.81M | -164.64%-21.35M | -91.02%2.87M | 97.10%-690.2K | -83.95%20.04M |
| Net Cash | -3,170.49%-462.59M | -1,859.42%-3.28B | -267.64%-851.66M | -189.73%-449.66M | 108.03%15.07M | -118.94%-167.36M | -110.93%-231.66M | 31.76%501.12M | -134.03%-187.7M | 7.45%883.68M |
| Begining period cash | -31.22%7.44B | -1.44%10.82B | -1.44%10.82B | -1.44%10.82B | -1.44%10.82B | 8.97%10.98B | 8.97%10.98B | 8.97%10.98B | 8.97%10.98B | 10.38%10.07B |
| Cash at the end | -36.07%6.92B | -31.22%7.44B | -7.59%9.91B | -9.91%10.34B | 0.31%10.82B | -1.44%10.82B | 7.28%10.72B | 9.49%11.48B | 1.77%10.79B | 8.97%10.98B |
| Cash balance analysis | ||||||||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion |
| Auditor | -- | PwC China (Special General Partnership) | -- | -- | -- | PwC China (Special General Partnership) | -- | -- | -- | PwC China (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"